Alps Advisors Inc. bought a new stake in EQRx, Inc. (NASDAQ:EQRX – Get Rating) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 289,355 shares of the company’s stock, valued at approximately $1,357,000. Alps Advisors Inc. owned about 0.06% of EQRx at the end of the most recent reporting period.
Other large investors have also recently bought and sold shares of the company. Pictet Asset Management SA purchased a new position in EQRx in the second quarter valued at $49,000. ProShare Advisors LLC acquired a new position in EQRx in the second quarter valued at $72,000. Virtu Financial LLC acquired a new position in EQRx in the first quarter valued at $64,000. Prelude Capital Management LLC acquired a new position in EQRx in the first quarter valued at $79,000. Finally, Mirabella Financial Services LLP acquired a new position in EQRx in the first quarter valued at $81,000. Hedge funds and other institutional investors own 80.38% of the company’s stock.
Wall Street Analyst Weigh In
Several research firms have issued reports on EQRX. Jefferies Financial Group downgraded shares of EQRx from a “buy” rating to a “hold” rating and decreased their price objective for the company from $5.60 to $3.20 in a research note on Friday, November 11th. The Goldman Sachs Group downgraded shares of EQRx from a “buy” rating to a “neutral” rating and decreased their price objective for the company from $8.00 to $5.00 in a research note on Friday, November 11th. Finally, JPMorgan Chase & Co. downgraded shares of EQRx from a “neutral” rating to an “underweight” rating in a research note on Monday, November 14th. One analyst has rated the stock with a sell rating, two have issued a hold rating and two have issued a buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $4.57.
EQRx Trading Down 0.6 %
EQRx Company Profile
EQRx, Inc, a pharmaceutical company, engages in developing medicines primarily for the treatment of oncology and immune-inflammatory diseases in the United States. The company's pre-registrational programs in Phase III clinical trial include Aumolertinib, an epidermal growth factor receptor (EGFR) inhibitor for the treatment of patients with EGFR-mutated non-small cell lung cancer (NSCLC); and Sugemalimab, an anti-programmed death-ligand 1 antibody for the treatment of Stage III and Stage IV NSCLC.
- Get a free copy of the StockNews.com research report on EQRx (EQRX)
- MarketBeat: Week in Review 11/14 – 11/18
- Target’s Double Bottom Might Have Just Been Confirmed
- How High Can the Fed Go? How to Trade it
- Verra Mobility Stock Has Returned Back to the Station
- Does ASML’s November Rally Have Staying Power?
Receive News & Ratings for EQRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EQRx and related companies with MarketBeat.com's FREE daily email newsletter.